Shao, Z., Hao, J., Wang, S., Zhang, Q., Gu, Y., Tian, F., Wang, S., Ouyang, Q., Zhang, L., Liu, Y., Cheng, J., Cang, S., Liu, Z., Xu, C., Nie, J., Lv, Y., Qian, J., Wang, T., Yu, M., Wu, F. (2025). Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.515